European Innovation Council

Releaf Paper is a producer of sustainable paper products from fallen leaves. They work on the task of finding a solution to achieve sustainability in the production of paper using new raw materials - fallen leaves, instead of wood.

Lactips is a French company founded in 2014 and headquartered in Lyon. It specializes in manufacturing biodegradable and water-soluble thermoplastic pellets derived from milk protein. The company employs a proprietary industrial process to produce these pellets quickly and in high volumes, making them suitable for various applications, including thermoforming and films. Lactips aims to offer its industrial clients innovative and sustainable alternatives to traditional oil-based plastics, aligning with its commitment to environmental sustainability and efficiency. By providing these disruptive solutions, Lactips supports its clients in accessing new markets while promoting a cleaner and more sustainable approach to plastic usage.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.

Osivax SAS is a clinical-stage biotechnology company based in Paris, France, founded in 2017. The company specializes in the development of innovative vaccines and immunotherapies aimed at addressing infectious diseases and enhancing immune responses. Its proprietary technology includes oligoDOM v1.0 and oligoDOM v2.0, which are designed to improve both B and T-cell immune responses by facilitating the uptake of antigens into dendritic cells. This results in more effective immune responses, including significant activation of CD8 T cells. Osivax's approach allows for the development of a universal vaccine targeting various infectious diseases, including influenza, malaria, and emerging coronavirus strains, while also showing potential applications in cancer treatment.